Therapeutic Fasting and Immune Aging
NCT05857241 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2025-04-08
Summary
Immunosenescence is the age-related decline of the immune system, involving a state of chronic inflammation and a decrease in the diversity/adaptability of the lymphocyte repertoire. The consequences of immunosenescence are multiple, including increased susceptibility to infections and poorer vaccine responses.
Conditions
- Fasting
- Diet, Healthy
Interventions
- DIETARY_SUPPLEMENT
-
Fasting mimicking diet (FMD)
D1 will correspond to a "pre-fasting" phase, with about 800 kcal of intake (approximately 40% of normal caloric intake) from a mono-nutrient diet (fruit, rice or potato according to the patient's preferences). Then D2 and D3 will correspond to the days of actual fasting, with 200-350 kcal of intake (10-18% of normal caloric intake) in the form of 100 ml of broth or vegetable juice (with a teaspoon of linseed oil) three times a day, and vaccination will take place on D4, after returning to a normal diet. 2 to 3 liter of water or unsweetened drink per day is required.Laxatives (unsweetened) will be prescribed and can be taken as during the fasting period.
Sponsors & Collaborators
-
Centre Hospitalier Universitaire de Saint Etienne
lead OTHER
Principal Investigators
-
Baptiste GRAMONT, MD · [email protected]
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-04-30
- Primary Completion
- 2026-02-28
- Completion
- 2026-03-31
Countries
- France
Study Locations
More Related Trials
-
Results of an Interferon-Gamma Release Assay After Treatment for Tuberculosis
NCT00595907 ·Status: COMPLETED
-
Trained and Heterologous Induced-immune Responses to Tropical Infectious Diseases
NCT05722054 ·Status: UNKNOWN
-
Nyaditum Resae® as a Co-adjuvant During Treatment for Active Pulmonary Tuberculosis and Its Impact on the Gut Microbiota
NCT03851159 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation
NCT04830462 ·Status: COMPLETED ·Phase: PHASE4
-
A Confirmatory Trial of Adjunctive NAC to Prevent Post Tuberculosis Lung Disease
NCT06909799 ·Status: RECRUITING ·Phase: NA
-
Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study
NCT05653193 ·Status: RECRUITING ·Phase: PHASE2
-
Immune Response to Mycobacterium Tuberculosis Infection
NCT00257907 ·Status: COMPLETED
-
Serological Test for the Diagnosis of TB
NCT02898623 ·Status: TERMINATED
-
Safety and Efficacy of Inhaled Interferon Gamma-1b in Pulmonary MAC Infection
NCT00043355 ·Status: TERMINATED ·Phase: PHASE2
-
Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs
NCT00201123 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Non-Tuberculous Mycobacterial Infections With Interferon Gamma
NCT00001318 ·Status: COMPLETED ·Phase: PHASE2
-
Interferon Gamma for Drug Resistant Tuberculosis
NCT00001407 ·Status: COMPLETED ·Phase: PHASE2
-
Reactogenicity, Safety and Immunogenicity of a TB/FLU-01L Tuberculosis Vaccine
NCT03017378 ·Status: COMPLETED ·Phase: PHASE1
-
Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients
NCT05841342 ·Status: UNKNOWN
-
Immune Responses to Mycobacterium Tuberculosis (Mtb) in People With Latent Tuberculosis Infection With or Without Concomitant Helminth Infection
NCT02225158 ·Status: TERMINATED
-
The Role of a Mycobacterium Growth Inhibition Assay to Quantify Host Immune Control of M. Tuberculosis
NCT06580639 ·Status: RECRUITING
-
Study to Evaluate the Tolerability and Immunogenicity of Nyaditum Resae ® Probiotic Administered to Pediatric Population in Contact With Tuberculosis With or Without Latent Tuberculosis Infection
NCT02581579 ·Status: COMPLETED ·Phase: NA
-
Host Response to Infection by Direct Analysis of Leukocyte Single Cell-type Gene Expression/transcript Abundance, Direct LS-TA. a Prospective Study Will Evaluate the Performance of Direct LS-TA in Triage Febrile Patients Into Major Categories of Infections: Viral, Bacterial or Active Tuberculosis.
NCT06846645 ·Status: NOT_YET_RECRUITING
-
Prospective Cohort of People Starting Treatment for Tuberculosis Disease in France (FrenchTB)
NCT06893757 ·Status: NOT_YET_RECRUITING
-
A Phase Ⅱ Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)
NCT05284812 ·Status: SUSPENDED ·Phase: PHASE2
-
Tuberculosis - Learning the Impact of Nutrition
NCT03598842 ·Status: COMPLETED ·Phase: NA
-
Iron Absorption and Utilization During Tuberculosis and After Treatment
NCT02176772 ·Status: COMPLETED
-
Impact of New Immunological Diagnosis Tests of Latent Tuberculosis Before Anti TNF Therapy
NCT00811343 ·Status: COMPLETED ·Phase: NA
-
Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients
NCT05571735 ·Status: RECRUITING
-
Lowering InterLeukin-1 Receptor Antagonist Concentrations After TB Treatment Onset
NCT04015713 ·Status: UNKNOWN